Next Article in Journal
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
Previous Article in Journal
Core-Fucosylated Tetra-Antennary N-Glycan Containing A Single N-Acetyllactosamine Branch Is Associated with Poor Survival Outcome in Breast Cancer
Previous Article in Special Issue
The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways
Article Menu
Issue 10 (May-2) cover image

Export Article

Open AccessReview

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease

1
Department of Paediatric Gastroenterology, The Erasmus MC Sophia Children’s Hospital, 3015 GD Rotterdam, The Netherlands
2
Department of Paediatric Gastroenterology and Nutrition, Kidz Health Castle UZ Brussels, Free University Brussels, B-1090 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(10), 2529; https://doi.org/10.3390/ijms20102529
Received: 1 April 2019 / Revised: 14 May 2019 / Accepted: 20 May 2019 / Published: 23 May 2019
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
  |  
PDF [430 KB, uploaded 23 May 2019]
  |     |  

Abstract

Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to insufficient growth and late pubertal development in cases of disease onset during childhood or adolescence. During the last decade, the role of anti-tumor necrosis factor (TNF) in the treatment of paediatric-onset IBD has gained more ground. The number of biologicals presently available for children and adolescents with IBD has increased, biosimilars have become available, and practices in adult gastroenterology with regards to anti-TNF have changed. The aim of this study is to review the current evidence on the indications, judicious use, effectiveness and safety of anti-TNF agents in paediatric IBD. A PubMed literature search was performed and included articles published after 2000 using the following terms: child or paediatric, Crohn, ulcerative colitis, inflammatory bowel disease, anti-TNF, TNF alpha inhibitor, infliximab, adalimumab, golimumab and biological. Anti-TNF agents, specifically infliximab and adalimumab, have proven to be effective in moderate and severe paediatric IBD. Therapeutic drug monitoring increases therapy effectiveness and safety. Clinical predictors for anti-TNF response are currently of limited value because of the variation in outcome definitions and follow-ups. Future research should comprise large cohorts and clinical trials comparing groups according to their risk profile in order to provide personalized therapeutic strategies. View Full-Text
Keywords: anti-TNF; biological; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; paediatrics; children; adolescents anti-TNF; biological; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; paediatrics; children; adolescents
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Aardoom, M.A.; Veereman, G.; de Ridder, L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int. J. Mol. Sci. 2019, 20, 2529.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top